Skip to content

The Network Pharmacology and Mechanism Analysis of Xianxiong Chengqi Decoction in Treating Hypertension with Phlegm and Blood Stasis Syndrome

The Network Pharmacology and Mechanism Analysis of Xianxiong Chengqi Decoction in Treating Hypertension with Phlegm and Blood Stasis Syndrome

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000031060
Enrollment
Unknown
Registered
2020-03-21
Start date
2020-03-31
Completion date
Unknown
Last updated
2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hypertension

Interventions

Sponsors

Affiliated Hospital of Shandong University of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 74 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the level 1 hypertension diagnosis standard in China hypertension prevention and control guidelines (2010). 2. Patients who meet the diagnostic criteria of syndrome type of phlegm and blood stasis syndrome in TCM syndrome differentiation and diagnosis. 3. Patients with stable blood pressure in the past 4 weeks, who have not been treated with traditional Chinese medicine or proprietary Chinese medicine, who have not been treated with western medicine for blood pressure reduction, or who have been treated with western medicine still belong to grade 1 hypertension. 4. Patients aged between 18-75 years (including 18 years old, excluding 75 years old), regardless of gender. 5. Patients who have clear mind, can understand and independently complete the questionnaire. 6. Patients who voluntarily participate in and cooperate with doctors and can sign written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with various secondary hypertension or refractory hypertension; 2. Patients with severe primary diseases such as brain, liver, kidney and hematopoietic system. 3. Pregnant or lactating women; 4. Patients after severe trauma or major surgery; 5. Patients with psychiatric diseases, malignant tumors or tuberculosis and other infectious diseases; 6. Patients who received clinical trials of other new drugs in the past three months; 7. Patients with allergic constitution and allergic to various drugs.

Design outcomes

Primary

MeasureTime frame
Mean dynamic blood pressure;symptom score of TCM;

Secondary

MeasureTime frame
Liver function;Renal function;???;Routine urine;Routine stool;ecg;

Countries

China

Contacts

Public ContactSu Wenge

Affiliated Hospital of Shandong University of TCM

suwenge68@163.com+86 13793188046

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026